Study of Minnelide™ in Patients With Advanced GI Tumors
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and the
dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™
recommended for future phase 2 protocol